Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Oct 04 04:00PM ET
9.25
Dollar change
+0.41
Percentage change
4.64
%
Index- P/E- EPS (ttm)-5.32 Insider Own8.45% Shs Outstand19.99M Perf Week-3.65%
Market Cap185.00M Forward P/E- EPS next Y-0.94 Insider Trans0.00% Shs Float18.31M Perf Month11.51%
Income-57.80M PEG- EPS next Q-0.16 Inst Own42.05% Short Float3.51% Perf Quarter-7.97%
Sales0.00M P/S- EPS this Y-202.19% Inst Trans- Short Ratio3.50 Perf Half Y-41.36%
Book/sh10.44 P/B0.89 EPS next Y-69.85% ROA-47.66% Short Interest0.64M Perf Year-53.39%
Cash/sh6.70 P/C1.38 EPS next 5Y- ROE-49.29% 52W Range6.50 - 28.04 Perf YTD-40.63%
Dividend Est.- P/FCF- EPS past 5Y-69.33% ROI-28.26% 52W High-67.02% Beta-
Dividend TTM- Quick Ratio41.70 Sales past 5Y-20.00% Gross Margin- 52W Low42.31% ATR (14)0.76
Dividend Ex-Date- Current Ratio41.70 EPS Y/Y TTM25.68% Oper. Margin0.00% RSI (14)51.98 Volatility7.82% 9.40%
Employees- Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price3.52
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q-955.73% Payout- Rel Volume0.50 Prev Close8.84
Sales Surprise- EPS Surprise-283.17% Sales Q/Q- EarningsAug 08 BMO Avg Volume183.85K Price9.25
SMA207.25% SMA50-2.50% SMA200-26.10% Trades Volume91,890 Change4.64%
Date Action Analyst Rating Change Price Target Change
Nov-19-21Downgrade Maxim Group Buy → Hold
Oct-03-24 07:30AM
Oct-01-24 07:30AM
Sep-24-24 07:30AM
Sep-19-24 05:38PM
07:26AM
07:55AM Loading…
Sep-04-24 07:55AM
Aug-27-24 07:01PM
Aug-13-24 07:30AM
Aug-08-24 07:36AM
Aug-07-24 07:30AM
Jul-08-24 08:38AM
Jun-27-24 12:00PM
Jun-26-24 07:41AM
Jun-19-24 07:30AM
Jun-11-24 09:35AM
07:30AM Loading…
07:30AM
May-29-24 07:30AM
May-14-24 07:30AM
May-06-24 08:32AM
Apr-25-24 07:30AM
Apr-18-24 07:30AM
Apr-16-24 07:30AM
Apr-10-24 07:30AM
Mar-19-24 11:53AM
Mar-18-24 07:30AM
Mar-15-24 07:30AM
Mar-14-24 07:30AM
Mar-13-24 07:00AM
06:00AM
Mar-12-24 10:37PM
07:30AM Loading…
Feb-27-24 07:30AM
Feb-14-24 07:45AM
Feb-07-24 07:30AM
Jan-28-24 05:02PM
Jan-24-24 09:00AM
Jan-23-24 07:30AM
Jan-08-24 07:34AM
Jan-04-24 07:32AM
Dec-06-23 07:30AM
Dec-05-23 07:30AM
Nov-30-23 07:30AM
Nov-20-23 07:30AM
Nov-16-23 07:30AM
Nov-15-23 07:30AM
Nov-14-23 07:16PM
01:00PM
Nov-10-23 08:13AM
08:05AM
08:03AM
Nov-03-23 07:40AM
Nov-01-23 03:32PM
07:30AM
Oct-31-23 09:00AM
07:45AM
Oct-29-23 05:17PM
Oct-26-23 07:30AM
Oct-25-23 07:30AM
Oct-23-23 07:33AM
Oct-17-23 05:35PM
Oct-12-23 05:00PM
Oct-06-23 07:30AM
Oct-04-23 07:30AM
Oct-03-23 07:30AM
Sep-27-23 07:30AM
Sep-26-23 07:30AM
Sep-25-23 07:30AM
Sep-21-23 05:00PM
07:30AM
Sep-05-23 07:30AM
Aug-28-23 01:23PM
10:57AM
09:22AM
Aug-23-23 09:37PM
Aug-21-23 01:40PM
Aug-17-23 07:30AM
Aug-15-23 07:52AM
Aug-14-23 07:30AM
Aug-04-23 09:46AM
Aug-02-23 07:30AM
Aug-01-23 09:32AM
Jul-31-23 06:29PM
Jul-27-23 07:30AM
Jul-26-23 07:30AM
Jul-24-23 07:55AM
Jul-20-23 05:01PM
08:00AM
Jul-17-23 08:44AM
Jul-12-23 07:30AM
Jun-30-23 07:30AM
Jun-29-23 05:00PM
Jun-27-23 05:00PM
07:30AM
Jun-21-23 07:30AM
Jun-15-23 07:30AM
Jun-08-23 07:30AM
Jun-05-23 07:30AM
Jun-01-23 07:30AM
May-30-23 05:46PM
May-24-23 07:30AM
May-09-23 07:30AM
Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.